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What’s COOKING

Guided by international guest chefs, occupational therapy students learn
food traditions — planning meals, following recipes, wearing native dress and
setting the table according to custom. Then, they enjoy the fruits of their labor.
Students cooked food from Ireland, Asia, India, Poland, Argentina, Colombia and
Ukraine. Leading the Nigerian cooking lab is Mary Adeniyi (back row, center),
whose husband and co-instructor, Sydney, is a Nigerian native.
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Researchers launch the first clinical trials
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dementia — can slow or stop the disease.

Sickle cell solutions

10

A novel procedure is gentler on patients
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Gabby Carter is among the
earliest sickle cell patients in the country
to be treated via an umbilical cord blood
transplant from an unrelated donor using
a reduced-intensity conditioning procedure
refined by Shalini Shenoy, MBBS, MD.
To learn more, turn to page 10.
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Researchers used a photoanalogue of propofol
to identify where it binds to GABAA receptors.
The small circles show the site.

Reducing risks

Propofol discovery may aid development of new anesthetics

R

esearchers at Washington University
School of Medicine and Imperial
College London have identified
the site where the widely used anesthetic
drug propofol binds to receptors in the brain
to sedate patients during surgery.
Until now, it hadn’t been clear how propofol connects with brain cells to induce
anesthesia. The researchers believe the findings, reported online in the journal Nature
Chemical Biology, eventually will lead to more
effective anesthetics with fewer side effects.
“For many years, the mechanisms by
which anesthetics act have remained elusive,” explained co-principal investigator
Alex S. Evers, MD, the Henry E. Mallinckrodt
Professor and head of the Department of
Anesthesiology. “We knew that intravenous
anesthetics, like propofol, act on an important receptor on brain cells called the GABAA
receptor, but we didn’t really know exactly
where they bound to that receptor.”
2 Washington University School of Medicine

Short-acting propofol often is used in
surgical patients. It wears off quickly and is
less likely to cause nausea than many anesthetics. But the drug isn’t risk-free. Potentially
dangerous side effects include lowered blood
pressure and interference with breathing.
To understand how propofol induces
anesthesia during surgery, scientists have
tried to identify its binding site within the
gamma-aminobutyric acid type A (GABAA)
receptor on brain cells. Activating these
receptors — with propofol, for example —
depresses a cell’s activity.

“For many years, the
mechanisms by which
anesthetics act have
remained elusive.”
— A L E X S. E V E R S, M D

Evers’ laboratory teamed up with a group
at Imperial College led by Nicholas P. Franks,
PhD, professor of biophysics and anaesthetics.
The group had created a photoanalogue of
propofol that behaves in precisely the same
way as propofol and contains a labeling group
that permanently attaches to its binding site
on the GABAA receptor when exposed to a
specific wavelength of light.
In creating the analogue, it’s as if the
researchers put a tiny hook onto the molecule
so that when it binds to the GABAA receptor,
it grabs onto the receptor and won’t let go.
“The next step was to extract the receptor,
cut it into pieces and identify the precise piece
of the protein where the propofol analogue
had attached to the receptor. This was the
tricky step that the Evers group at Washington
University had perfected,” Franks said.
Evers and Franks believe this technique has
implications for other types of drugs beyond
anesthetics, such as psychiatric agents and
anti-seizure drugs.
“By understanding precisely what the binding sites look like on the proteins that induce
those potential problems, we eventually hope
to design and select for drugs that have the
benefits we want without dangerous side
effects,” Evers said.
Winter 2013–14

Genetic errors found repeatedly
in 12 of the major cancer types

“This is just the
beginning.” —
Li Ding, PhD
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Examining 12 major types of cancer, scientists at Washington
University School of Medicine have identified 127 repeatedly
mutated genes that appear to drive the development and progression of a range of tumors in the body. The discovery sets
the stage for devising new diagnostic tools and more personalized cancer treatments.
The research, published Oct. 17 in Nature, shows that some
of the same genes commonly mutated in certain cancers also
occur in seemingly unrelated tumors. For example, a gene
mutated in 25 percent of leukemia cases in the study also was
found in tumors of the breast, rectum, head and neck, kidney,
lung, ovary and uterus.
Based on the findings, the researchers envision that a single
test — one that surveys errors in a swath of cancer genes
— eventually could become part of the standard diagnostic
workup for most cancers. Results of such testing could guide
treatment decisions for patients based on the unique genetic
signatures of their tumors.
While earlier genome studies typically have focused on
individual tumor types, the current research is among the
early studies to look across many different types of cancer.
“This is just the beginning,” said senior author Li Ding,
PhD, of The Genome Institute at Washington University.
“Many oncologists and scientists have wondered whether
it’s possible to come up with a complete list of cancer genes
responsible for all human cancers. I think we’re getting
closer to that.”
Researchers analyzed genes from 3,281 tumors — a collection
of cancers of the breast, uterus, head and neck, colon and
rectum, bladder, kidney, ovary, lung, brain and blood.
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Setting the stage for new diagnostic tools

Model program

Local youth celebrate the fifth anniversary of The SPOT (Supporting Positive Opportunities with Teens).
Federal and Illinois health officials recently tapped The SPOT as
a mentor for a similar center in East St. Louis, Ill. Aimed at 13- to
24-year-olds, The SPOT offers free testing for HIV and sexually transmitted diseases, health care and counseling, social support and more.
School of Medicine clinicians and staff provide many of the services.

Breast cancer test earns FDA approval
A lab testing kit that estimates the risk of breast cancer
returning after anti-hormone treatment has received U.S.
Food and Drug Administration approval. The technology
could help standardize breast cancer diagnosis, according to
School of Medicine researchers, who led the development.
The research team, including collaborators at the
University of North Carolina, the University of Utah and
the BC Cancer Agency in Canada,
designed a test that categorizes breast
tumors into four main types by looking
at the expression of 50 genes. Each subtype has a distinct genetic signature and
requires a different treatment approach.
These subtype data then are combined
with a standard pathology variable to
deliver a “risk of recurrence” score that
predicts the likelihood of that patient’s
disease returning within 10 years.
The test, Prosigna, removes some of the
Will the cancer return?
subjectivity that goes into breast cancer
diagnosis, which still involves looking at cells under a microscope and, based on visual cues, determining how aggressive
the tumor is likely to be.
“With this test, we are moving toward a standardized
diagnosis based on the genetics of the tumor,” said Matthew
J. Ellis, MB, BChir, PhD, test co-inventor and oncologist at
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital
and Washington University School of Medicine.
Outlook 3

pulse
Trio of Wolff Professors honored
in Department of Medicine

Mindful approach

Kevin Parks, third-year medical
student and volunteer with the Young Scientist Program, recently
shared the wonders of the brain with the general public at Brain
Works. The event at The Ritz-Carlton, St. Louis, featured hands-on
demonstrations, including the chance to hold a real human brain,
and a presentation by Washington University neurosurgeons Eric
Leuthardt, MD, and Albert Kim, MD, PhD. Among other topics,
attendees learned about innovative therapies and technologies.

Evaluating red blood cell storage
Washington University School of Medicine has received a
$7.8 million grant to determine whether the length of time
red blood cells (RBCs) are stored affects organ failure in
critically ill children who receive RBC transfusions.
The five-year grant, from the National Heart, Lung and
Blood Institute of the National Institutes of Health (NIH), will
fund a trial involving more than 1,500 critically ill children who require RBC transfusions at St. Louis Children’s Hospital
and some 30 other medical centers in
the U.S. and Canada. The trial will
be one of the largest studies performed in pediatric critical care.
“We want to know whether fresh
red cells can improve outcomes in
critically ill children,” said Philip
Spinella, MD, associate professor of
pediatrics at the School of Medicine
and a principal investigator in the study.
“No studies have evaluated whether storing RBCs for more
than a week affects clinical outcomes for these children.”
The researchers will compare the risk of new or progressive
multiple organ failure in two groups of critically ill children
ages 3 days to 16 years randomly assigned to receive RBC
transfusions as a course of treatment. One group will receive
RBCs stored for a week or less, and the other will receive
RBCs stored an estimated average of 21 days.
Generally, patients who require RBC transfusions receive
Enjoy interactive elements and added content
cells stored anywhere from three to 42 days. The standard
approach is to use those stored the longest first.
4 Washington University School of Medicine

Three highly regarded faculty members in the Department
of Medicine have been named Alan A. and Edith L. Wolff
Professors in their fields. They are Daniel C. Brennan, MD,
Chyi-Song Hsieh, MD, PhD, and Daniel S. Ory, MD.
A bequest by the late Edith L. Wolff to enable these and
other professorships continues the legacy of support for
medical research that characterized Edith L. Wolff’s life and
that of her husband, the late Alan A. Wolff.
Daniel C. Brennan, MD, is the Alan A. and Edith L. Wolff
Professor of Renal Diseases. He is a professor of medicine
and director of transplant nephrology at the School of
Medicine. Brennan joined the faculty in 1993 as the first
director of transplant nephrology. He is internationally
known for his studies on infectious complications of kidney
transplants, and his research has resulted in new anti-rejection strategies that have markedly improved kidney transplantation outcomes.
Chyi-Song Hsieh, MD, PhD, the Alan A. and Edith L.
Wolff Professor of Rheumatology, is an associate professor
of medicine and of pathology and immunology. Hsieh, who
studies autoimmune diseases, joined the medical school
in 2005 and has conducted groundbreaking research in
basic immunology.
Daniel S. Ory, MD, the Alan A. and Edith L. Wolff
Professor of Cardiology, is a professor of medicine and of cell
biology and physiology. He is co-director of the BioMed 21
Diabetic Cardiovascular Disease Center and director of the
Washington University metabolomics facility. He also is
director of admissions for the Division of Biology and
Biomedical Sciences. He joined the faculty in 1995.

ROBERT BOSTON

CLAUDIA BURRIS

Look for

Daniel C. Brennan, MD, Chyi-Song Hsieh, MD, PhD, and Daniel S. Ory, MD
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Taylor Institute launch

Shown are Taylor Family Institute investigators: (back row, left to right) David Wozniak, PhD; David Reichert,
PhD; Charles Zorumski, MD; Joe Henry Steinbach, PhD; (middle row) Alex Evers, MD; Douglas Covey, PhD;
Gustav Akk, PhD; (front row) Ziwei Chen, PhD; Yuki Izumi, MD, PhD; and Steven Mennerick, PhD.

An Oct. 1 celebration marked the official
launch of the Taylor Family Institute for
Innovative Psychiatric Research. Dedicated to
developing new and more effective therapies
for psychiatric disorders, the institute was
created with a $20 million gift from Andy
and Barbara Taylor and the Crawford Taylor
Foundation, the charity of the entire Jack C.
Taylor family. The institute, housed in the
Department of Psychiatry, includes members
from four School of Medicine departments.
Research initially will focus on neurosteroids,
naturally occurring chemicals in the brain
involved in regulating cognition, emotion
and motivation. For more information, visit
taylorfamilyinstitute.wustl.edu.

U S E R - F R I E N D LY DATA BA S E

Matching genes with potential therapies

A

massive online database now
matches thousands of genes linked
to cancer and other diseases with
drugs that target those genes. Some of the
drugs are approved by the U.S. Food and
Drug Administration, while others are in
clinical trials or just entering the drug
development pipeline.
The database was developed by identical twin brothers, Obi Griffith, PhD, research
assistant professor of medicine, and Malachi
Griffith, PhD, research instructor in genetics,
whose interest in pairing drugs with genes
is as much personal as it is scientific. Their
mother died of breast cancer 17 years ago,
weeks before their high school graduation.
“We wanted to create a comprehensive
database that is user-friendly, something
along the lines of a Google search engine for
disease genes,” explained Malachi Griffith.
“As we move toward personalized medicine,
there’s a lot of interest in knowing whether
drugs can target mutated genes in particular
patients or in certain diseases, like breast or
lung cancer. But there hasn’t been an easy
outlook.wustl.edu

way to find that information.”
Details of the Drug Gene Interaction
Database were reported online Oct. 13 in
Nature Methods. The database also includes
genes involved in Alzheimer’s disease, heart
disease, diabetes and many other illnesses.
The Griffiths created the database with a team
of scientists at The Genome Institute
at Washington University.
The database is easy to search and geared
toward researchers and physician-scientists
who want to know whether errors in disease
genes — identified through genome sequencing or other methods — potentially could
be targeted with existing drug therapies.
Additional genes included in the database
could be the focus of future drug development efforts because they belong to classes
of genes that are thought to make promising
drug targets.
“Developing the database was a labor
of love for the Griffiths,” said senior author
Richard K. Wilson, PhD, director of The
Genome Institute. “There’s an amazing depth
to this resource, which will be invaluable to

researchers working to design better treatment
options for patients.”
Wilson and his colleagues caution that the
database is intended for research purposes
and that it does not recommend treatments.
The primary purpose of the database is to
further clinical research aimed at treating
diseases more effectively.
The free, publicly available database brings
together information from 15 publicly available
databases in the U.S., Canada, Europe and Asia.
To access it, visit dgidb.genome.wustl.edu.
Outlook 5
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NIH grants total $26 million
for leukemia research
Support for basic science, clinical trials
Michael M. Awad, MD, PhD

Valerie S. Ratts, MD

Educational leadership

Michael M. Awad, MD,
PhD, assistant professor of surgery, now is associate dean for medical
student education and Valerie S. Ratts, MD, professor in obstetrics and
gynecology, has been named associate dean for admissions. Awad
will oversee the medical student curriculum (managing schedules,
evaluations, assessment, course planning and the Career Counseling
Office). Ratts will direct all aspects of medical school admissions,
working to attract, recruit and enroll the best students.

Two elected to Institute of Medicine
Evan D. Kharasch, MD, PhD, and J. Evan Sadler, MD,
PhD, have been elected to the Institute of Medicine of the
National Academy of Sciences, one of the highest honors
medical scientists in the U.S. can receive.
Kharasch and Sadler, both widely
regarded physician-scientists at
Washington University School of
Medicine, are among 70 new
members and 10 foreign associates whose elections to the
Institute of Medicine recently
were announced by the
National Academy of
Sciences.
Members are selected
based on their professional
achievements and commitment to service. As members,
Kharasch and Sadler will devote
a significant amount of volunteer
time on committees engaged in a
broad range of health-policy issues.
Kharasch, the Russell D. and Mary B. Shelden Professor
of Anesthesiology and professor of biochemistry and
molecular biophysics, is also the vice chancellor for
research at Washington University.
Sadler is professor of medicine and of biochemistry
Enjoy interactive elements and added content
and molecular biophysics and chief of the Division of
Hematology at the School of Medicine.
6 Washington University School of Medicine

The National Cancer Institute, part of the National Institutes
of Health (NIH), has awarded two major grants totaling $26
million to leukemia researchers and physicians at the Alvin
J. Siteman Cancer Center at Barnes-Jewish Hospital and the
Washington University School of Medicine.
The funding helps establish the medical school as a premier center for innovative leukemia research, with a benchto-bedside approach that has the potential to lead to novel
therapies that improve survival and reduce treatment-related
side effects.
The first award is a five-year, $14.3 million Program
Project Grant (PPG) in leukemia. The grant initially was
funded at the medical school in
2003 and has been renewed
twice. With new support,
the scientists aim to
identify all the genetic
changes underlying
the development and
progression of acute
myeloid leukemia, the
most common type of
acute leukemia in adults.
This information may
lead to more personalized
treatments for patients based
on the unique genetic and
Investigating the
molecular signatures of their
genetic origins of acute
leukemia cells.
The second award is
myeloid leukemia
a prestigious Specialized
Program of Research Excellence (SPORE) grant in leukemia.
The $11.3 million, five-year award capitalizes on research
advances at the medical school to bring new investigational
treatments into clinical trials.
Timothy Ley, MD, the Lewis T. and Rosalind B. Apple
Chair in Oncology, is principal investigator of the Program
Project Grant; Daniel Link, MD, the Alan A. and Edith
L. Wolff Distinguished Professor of Medicine, is principal
investigator of the SPORE grant.
“There’s important synergy between the two grants,”
said Ley. “The PPG focuses on basic research to generate
ideas, concepts and technologies that can be evaluated in
clinical trials via the SPORE grant.”
As part of the research, Division of Oncology scientists
will work closely with researchers at The Genome Institute
to further explore the genetic basis of leukemia.
Winter 2013–14

PREVENTING
ALZHEIMER’S

Can it be done? A groundbreaking study aims to find out.

BERNARD BECKER MEDICAL LIBRARY ARCHIVES AND RARE BOOKS • DIANTU

BY MICHAEL
C. PURDY

TOP: In a 1911 article, Alois
Alzheimer described the symptoms
of his patients and illustrated the
neurofibrillary tangles and amyloid
plaques found during post-mortem
analyses of their brains.
LEFT: Today, scanning confirms
extensive changes in the brain of
someone with Alzheimer’s disease.
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A L Z H E I M E R’S D I S E A S E T R I A L

Is it possible to curtail Alzheimer’s early stages?

Before damage is done
Two drugs targeting the protein amyloid beta (Aβ) could
stop it from damaging the brain before any symptoms occur.
As visualized below, an antibody called solanezumab (s)
removes soluble molecules of Aβ (yellow). Another antibody,
gantenerumab (g), binds to and removes larger aggregates of Aβ.

s

g

M O R E T H A N A C E N T U R Y A G O,
Alois Alzheimer, a German psychiatrist,
first identified the neurodegenerative
brain condition that came to be known as
Alzheimer’s disease.
Finding ways to diagnose and treat this
devastating disease has frustrated scientists
and clinicians ever since.
Now the long and hard-fought campaign
against Alzheimer’s has reached a potentially
significant milestone: the launch of the
first clinical trials to test whether new drug
treatments given before dementia can prevent
the disease.
The trial is being conducted by the
Dominantly Inherited Alzheimer’s Network
Trial Unit (DIAN-TU), led by principal
investigator Randall J. Bateman, MD, the
Charles F. and Joanne Knight Distinguished
Professor of Neurology at Washington
University School of Medicine.
Learn more about the registry:

w w w. DIANXR .or g
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~20–30 YRS PRIOR

~15 YRS PRIOR

Cerebrospinal fluid analysis
reveals abnormal levels
of precursor proteins, an
early warning sign

Neurofibrillary tangles (gray)
have already gnarled some tissue;
amyloid beta protein (yellow)
deposits in clumps

Steps on the journey School of Medicine researchers have

made many key contributions along the journey to the new
DIAN-TU trial.
The late Leonard Berg, MD, the founding director of the
university’s Knight Alzheimer’s Disease Research Center, and
current director John C. Morris, MD, were among the first to
assert and prove that Alzheimer’s harms patients’ brains for
many years prior to dementia onset and memory loss.
Washington University scientists have led the quest for
new treatments and for biological markers that can identify
people who seem normal but whose brains are actively being
damaged by presymptomatic Alzheimer’s disease.
Researchers have characterized disease markers in cerebrospinal fluid and have tested neuroimaging techniques
for detecting Alzheimer’s, making it possible to diagnose
the disease much earlier.

A long, slow descent Rare, inherited forms of Alzheimer’s

are particularly devastating — striking much earlier in life
than sporadic forms of the disease — with symptoms becoming apparent in some mutation carriers in their 30s or 40s.
Children who inherit one of the mutations typically show
signs of Alzheimer’s at about the same age as their parents.
To expand researchers’ opportunities to work with these
families, Morris founded the Dominantly Inherited Alzheimer’s
Network (DIAN) in 2008. This global network generated a
pool of qualified volunteers and forged a research partnership determined to understand forms of Alzheimer’s caused
by genetic mutations.
With the help of DIAN family members, researchers
created a detailed timeline of the brain’s long, slow descent
into Alzheimer’s dementia, showing, for example, that brain
plaques can be detected 15 years prior to symptoms. These
plaques are made mostly of amyloid beta. This protein,
which abnormally accumulates in the brain of people with
Alzheimer’s, is thought to play a role in brain cell damage
and death.
Winter 2013–14

Treatments at later stages have been unsuccessful

~ 10 Y R S P R I O R

~5 YRS PRIOR

ALZHEIMER’S

3 – 7 Y R S U N T I L D E AT H

Protein deposits increase,
with negative
effects on cognitive
functions

Tissue begins to atrophy
and shrink; some clinical
measures can detect
a functional decline

Difficulties due to memory
and cognitive loss; impaired
function in job
and social activities

Marked decline as the person
becomes increasingly demented,
culminating in disability
and finally death

Starting the new trial With the support of these find-

ings and other groundwork from the DIAN study, Bateman
established the DIAN Trials Unit. Now, DIAN participants
and others who have an inherited Alzheimer’s mutation are
undergoing the first trials of preclinical treatments that target amyloid beta. Many of these participants do not have
any symptoms, but researchers know these patients will get
Alzheimer’s disease and approximately when they will get it.
“Trying to prevent Alzheimer’s symptoms from occurring
is a new strategy, but much of what we’ve learned in recent
years about Alzheimer’s and the brain has suggested that
prevention has a significantly better chance of succeeding
than treatment after cognitive impairment,” said Morris, the
Harvey A. and Dorismae Hacker Friedman Distinguished
Professor of Neurology.
The trial is testing two drug treatments
designed to eliminate amyloid beta from the
brain at different points in the plaque production
process. Researchers plan to test additional treatments with different mechanisms of action in this
and future trials. The treatments were nominated
by the DIAN Pharma Consortium, composed
of 11 pharmaceutical companies that have been
advising researchers on the planning of the trial.
From those nominations, the Alzheimer’s
researchers chose the trial drugs.
“We believe that the diverse portfolio of drugs and
approaches of the DIAN-TU trial will accelerate the discovery of an effective treatment for Alzheimer’s,” Bateman said.
“This trial is possible because of the outstanding support of
multiple stakeholders, including patients and family members, pharmaceutical partners, the Alzheimer’s Association,
the National Institutes of Health, academic researchers and
highly dedicated trial operations groups.”
The trial is funded by a unique mix of private and
public resources, including: major grants from the
National Institutes of Health (NIH) and the Alzheimer’s
outlook.wustl.edu

Association; treatment donations and funding from the
drugs’ manufacturers Roche and Eli Lilly & Co.; donation
of a new agent for imaging brain plaques, Amyvid, by Avid
Radiopharmaceuticals Inc., a wholly owned subsidiary of
Lilly; and donation by CogState of computerized cognitive
skills tests to help assess function in participants.

Renewed hope This initial study involves 210 participants.
Three of every four will receive active forms of trial drugs; the
fourth will receive a placebo. Researchers will track biological markers of Alzheimer’s in participants’ cerebrospinal fluid
and on brain scans, looking for any indicators that the disease
process is slowing or stopping.
If successful, scientists plan to move directly into Phase
III clinical trials to prove that Alzheimer’s can be slowed

Prevention, the research suggests, has
a better chance of succeeding than
treatment after cognitive impairment.
or stopped. The hope is that knowledge gained in the trials
can be applied to the more common late-onset Alzheimer’s.
Brent Whitney, 34, of Grove, Okla., is asymptomatic, but has
an inherited form of Alzheimer’s and is a DIAN participant.
The lives of his grandmother and 10 of her 13 siblings were
cut short by the Alzheimer’s gene mutation, and the mutation
continues to affect succeeding generations of the family.
“The start of this trial is a very exciting moment in
Alzheimer’s disease research, and it gives me renewed hope
for a future without Alzheimer’s,” Whitney said. “I hope my
grandchildren someday learn of this condition in history
books, like I learned about polio.”
Outlook 9
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for transplants
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BY STEVE KOHLER

A reduced-intensity conditioning process —
gentler than the harsh chemotherapies used
in the past — will safely prepare Judah Wilks’
body to accept a stem cell transplant for his
sickle cell disease.

Outlook 11

refining a safer, gentler process
that promises a long-term fix
for sickle cell disease

GABBY

June 2012

N J U N E O F 2 0 1 2 , 6-year-old Gabby Carter reached
a watershed moment in her young life. Having lived with
sickle cell disease and its debilitating effects since the time
of her first medical crisis at 10 months of age, she arrived
at transplant day.
Gabby needed more than 30 blood transfusions and
made 50 trips to St. Louis Children’s Hospital from her Cape
Girardeau, Mo., home to manage her condition. Sickle cell
disease (SCD) is marked by a host of symptoms, including
sudden pain throughout the body. Although Gabby
never suffered a stroke, many SCD patients do, and
the threat is always present.
first recipients of
The transplant itself must have seemed eerily
unrelated cord blood
transplants using
anticlimactic. Right there in her all-too-familiar
reduced-intensity
hospital room, a bag of what appeared to be oddly
conditioning
colored blood hung next to her, and, under the
direction of Shalini Shenoy, MBBS, MD, its contents flowed
into Gabby’s veins. No operating room, nary a scalpel, and the
next day, Gabby was up and moving around.
If all went as planned, these donated cord blood stem
cells would find their way to Gabby’s bone marrow and begin
producing normal, oxygen-carrying red blood cells, replacing
her defective sickle cells.
Although the procedure was less than dramatic, Gabby’s preconditioning to receive it was finely tuned. And the 18 months
post-transplant have been a closely monitored “tightrope walk,”
according to Shenoy.
Today, Gabby’s sickle cell disease (SCD) is gone — cured.
Now, her mom, Debbie, says Gabby’s a vibrant 7-year-old
who has played in the snow, gone swimming and attends
second grade with her classmates.

fresh
starts

C A I T LY N

JUDAH

May 2013

October 2013
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Gabby is among the earliest sickle cell patients
in the country to be cured via an umbilical cord
blood transplant from an unrelated donor using a
reduced-intensity conditioning procedure refined
at Washington University School of Medicine.
The novel procedure is remarkable for two primary reasons: It is much gentler on patients than
earlier procedures; and it dramatically will expand
an extremely limited donor pool.

upping the odds
A renowned leader in pediatric stem cell transplantation, Shenoy is the Teresa J. Vietti, MD Scholar in
Pediatrics and directs the Pediatric Bone Marrow
Transplant Program at St. Louis Children’s Hospital
and the Alvin J. Siteman Cancer Center at BarnesJewish Hospital and Washington University School
of Medicine.
Shenoy is leading a 20-center pilot study
focused on reduced-intensity cord blood transplants from unrelated donors. The study has a
safety restriction: three patients must have successful transplants before three more can be performed. Following the completion of nine patients,
Shenoy is hopeful that the pilot study will extend
to a fully funded national trial by the end of 2014.
Since Gabby’s transplant, two other children —
Caitlyn Hill and Judah Wilks — have undergone
the procedure at St. Louis Children’s Hospital.
Up until now, treatment options for children
were limited. One option was to find an exact
bone marrow match, but that’s difficult. African
Americans, who make up the majority of the

5

sickle cell population, are vastly underrepresented
in national marrow registries. The other option
was to use umbilical cord blood from a tissuematched sibling free from the disease.
Nimble newborn cord blood offers significant
benefits over bone marrow, requiring a less stringent match and fewer cells to effect a cure. Even
so, tissue-matched sibling donors often are not
available. Unrelated cord blood is easier to find
because many public banks have made minority
cord blood donation a priority. However, unrelated cord blood transplants simply weren’t very
successful.
“You have better chances of finding a cord
match than a marrow,” Shenoy said. “It was
important for us to find a successful way.”

Checking in post-transplant,
Caitlyn Hill and her mom,
Lena, review progress with
nurse practitioner Monica
Hente. Inset: Some of the
meds Caitlyn was taking to
help her body readjust as
the transplant takes hold.

things to know about sickle cell disease
About 100,000 Americans live
with SCD. It is the most common
inherited blood disorder in
the U.S.

PHOTOS BY ROBERT BOSTON

Sickle cell affects those with
African, Spanish, Mediterranean
and Indian ancestry. In the
U.S., about one in 500 African
Americans and one in 1,200
Hispanic Americans are born
with SCD.
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SCD occurs when a child
inherits two sickle hemoglobin
genes, one from each parent.
People are born with sickle cell;
it doesn’t develop later in life
and it’s not contagious.
The dysfunctional genes
produce red blood cells with a
distinctive sickle shape, jagged
edges and a brittle structure.
These cells clump together, and

intense pain results as blocked
and damaged arteries starve
organs and systems of oxygen.
Anemia is the No. 1 symptom.
SCD is a chronic illness, but with
new therapies, many people
are living more productive lives.
Life expectancy has increased
from 14 years to 50 and older.
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improving the process

Shalini Shenoy, MBBS, MD, gives Gabby the OK to stop taking protective
post-transplant medications — and jump into a life without sickle cells.

Researcher sets national standards

T

hat the reduced-intensity
unrelated cord blood transplants succeed is a tribute to
Shenoy’s tenacity. The wider medical community largely abandoned
reduced-intensity cord blood
transplants following early failures,
reverting to myeloablative conditioning with siblings only.
Just eight years earlier, myeloablative conditioning in bone marrow
transplants from unrelated donors
also was considered too toxic
for patients. But Shenoy devised
a reduced-intensity transplant
approach. Based on her experience,
the first unrelated donor bone marrow transplant trial for sickle cell
disease was opened through the
National Heart, Lung and Blood
Institute’s Bone Marrow Transplant
Clinical Trials Network. Shenoy is
principal investigator for this trial.
Reduced-intensity unrelated
transplants for sickle cell began
succeeding with bone marrow, but
initially failed with umbilical cord
blood. Shenoy persevered, further
fine-tuning the pharmaceutical
cocktail and tweaking the protocol
until unrelated cord blood trans14 Washington University School of Medicine

plants also began working.
Despite the disease’s severity
and the procedure’s complexity,
Shenoy now achieves successful
donor cell engraftment using both
unrelated donor bone marrow and
cord blood products.
John F. DiPersio MD, PhD, chief
of the Division of Oncology and
deputy director of the Siteman
Cancer Center, hails Shenoy’s work.
“Her clinical studies will have a
transformative impact on the
future success of both related and
unrelated stem cell transplant for
children with sickle cell anemia,
resulting in restoration of normal
blood production while minimizing the usual toxicities of unrelated
stem cell transplants.”
Shenoy’s reduced-intensity
approach since has been applied
in bone marrow transplants for
another condition, thalassemia,
in a national trial, which used the
modifed approach successfully
and included unrelated cord blood
transplants. Shenoy and others now
are testing similar methods to treat
several non-cancerous immune and
marrow failure disorders.

Cord blood transplants — regardless of source
— carried an important drawback: they required
that all of a recipient’s blood-producing cells first
be eliminated via high-dose chemotherapy, a toxic
pre-transplant process known as myeloablative
conditioning. Despite this, many patients rejected
cord blood cells from unrelated donors. Even if
the cells engrafted successfully, curing the disease,
patients often had unwanted collateral organ
damage, a high incidence of sterility and liver
dysfunction. A less toxic option using cord blood
was needed.
Shenoy’s reduced-intensity conditioning
avoids major organ damage. It forces the patient’s
immune system to accept the new cells — a balancing act that requires judgment and experience.
Too little conditioning will cause the donor cells
to be rejected, but too much can cause prolonged
immune suppression.
In particular, to prevent rejection,
the T-cells of the recipient’s
immune system must be
depleted, making it possible to slip in the new
cells. This is done via
low-dose chemotherapy and monoclonal
antibodies.
In this method, the
donated cord blood still
must be tissue-matched
for compatibility, but
importantly, can come either
from a sibling or from the widely
available unrelated donor pool.

this therapy
avoids the
long-term
damages
of prior
methods

watching the risks
For the critical month following the cord blood
transplant, the patient is sustained by transfused
red blood cells and platelets. Over time, the new
cells begin to work. SCD patients need as much as
a year of recovery as the new cells become prolific
and establish an operative immune system.
Shenoy monitors what she calls the “big three”
risks. First is infection. With a downsized old
immune system and a new one not yet fully functional, infection is a constant threat and must be
treated promptly.
The second is rejection. Rejection can occur
when the patient’s remaining immune system
identifies the transplant as foreign and attacks the
Winter 2013–14

transplants,
made better

T

he standard sickle cell treatment
— engrafting a new hematopoietic (blood-forming) system created
from donor cells — has been harsh
medicine. Donor bone marrow cells
must exactly match eight cellular
biomarkers in the recipient. Further,
recipients endure strong chemotherapy
to destroy the old system before
building a new one. By contrast, an
improved treatment draws from a
larger pool of cord blood donors
and uses safer, gentler conditioning.

MATCHING
A successful cord
blood donation must
match only five of
the recipient’s
eight immune cell
biomarkers
(white).

new cells. Shenoy uses DNA tests to determine the
source — new or old — of the gradual increase in
red blood cells. She says some mixed chimerism
— carrying two DNA sets (patient and donor) —
is acceptable, even long term, but she stays alert
to any drop in productivity of the new cells.
The third is rejection’s sneaky counterpart:
graft versus host disease (GVHD), which can
quickly ruin everything. In GVHD, the transplanted cells’ immune components identify the
patient’s body as foreign and attack it. The results
are difficult to treat, and treatment causes further
immune suppression resulting in a cycle of
infection and GVHD.

PHOTOS BY ROBERT BOSTON

expecting the best
For many, Gabby included, the year posttransplant is tough. She needed 50 medications,
including 15 IVs for blood pressure control,
diabetes regulation and steroids to manage GVHD.
It wasn’t easy avoiding crowds and eating a healthful diet. But she followed the regimen and came
through, with the benefits afforded by reducedintensity conditioning: no cognitive impairment,
no liver or kidney dysfunction and no discernible
fertility damage. Not surprisingly, mom Debbie
now struggles to maintain the tight control she
adopted to protect her daughter.
Because strokes often recur with SCD and
damage accumulates over time, Shenoy said
it’s advantageous to intervene early. But only
when the risk-to-benefit ratio with transplant
has been shown to be positive.
That’s why 2-year-old Judah Wilks underwent
a transplant last fall. Whereas the average age of
outlook.wustl.edu

CONDITIONING Reducedintensity conditioning agents
“downsize” the recipient’s
immune system to avoid
rejection without causing
problems during or after
the transplant.
TRANSPLANT The donor cells
are implanted. Caregivers must
balance risk factors and manage
the recipient’s health for a few
months until the transplanted
cells establish a stable new
blood and immune system.

first stroke for a SCD patient is 9 years, Judah
suffered his first stroke 10 months ago.
Judah’s parents, Bryce and Maryl Wilks of
Marshfield, Mo., adopted him and his brother,
David, from the Democratic Republic of the Congo.
The family learned of Judah’s SCD only when the
standard tests that all U.S. infants receive were run
upon his arrival in this country.
People of deep faith, the Wilks firmly believe it
is no accident that they found Judah and that he
is now part of their Missouri family and close to
Shenoy’s groundbreaking program. Bryce said of
the post-transplant future, “We expect the best.”
That fervent belief — along with Shenoy’s
attention to balance in applying her novel
approach to transplant —
suggests they will
get nothing
less.

Judah Wilks with Megan
Holtmann, stem cell transplant nurse coordinator at
St. Louis Children’s Hospital.
The conditioning already
underway, Judah played
with Megan, read books with
his brother, hugged his mom
and mugged for the camera —
testimony to the general
mildness of the transplant
preparations.
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Exploring

AN

A traditional course of study evolves with
its field and embraces contemporary
technologies. From left: anatomy
instructors Jane Phillips-Conroy, PhD,
Glenn Conroy, PhD, and Krikor Dikranian,
MD, PhD.
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H

human

uman anatomy is the flagship course of first-year study.
Students unravel miles of vessels, dissect masses of tissue, find
and name interlinking parts and consider functional systems. Dry
textbook abstractions become viscerally real. During a life-changing
semester, students ponder the human organism, developing the
respect and detachment physicians must cultivate in their duties.
Students huddle, four to a cadaver,
around each stainless steel table. “The first
day is daunting,” said course master Glenn
C. Conroy, PhD. “For many, it’s their first
exposure to death. And it’s a challenging
and humbling experience to make that first
incision into the human body.”
Many donors beforehand write letters
about their lives and medical histories,
which are placed alongside their bodies.
Students employ electronic tablets
“Their last wish was to provide useful
and study radiologic anatomy on large
information to tomorrow’s physicians,”
wall monitors in the renovated lab.
Conroy said. “We tell the students, ‘You are
the instrument through which their final wishes are manifested.’”
The donors, in a sense, become the students’ first patients.
Recently renovated, the century-old lab showcases the school’s
expansive anatomical specimen collection. Anatomists of old would
marvel at the glowing high-definition wall monitors and iPads.
Throughout weeks of exploration, feelings of insecurity
eventually yield to fascination. “You can see the students evolving
in front of your eyes,”
Conroy said.
Practicing specialists
visit the class to offer clinical
contexts for the examples
upon the tables. During exams,
students must think on their feet when asked questions designed
to synthesize their analyses of the cadavers.
The course concludes with an evening of reflection; students
offer memorial poems, essays and musical tributes to the donors.
Through exploring these human bodies, future physicians
come to better know themselves: a vital passage toward mastering
the art and science of improving human health.

ATOMY
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A quartet of arts specialists, photographed at Powell Symphony Hall in St. Louis:
Devyani Hunt, MD, Lynnette Khoo-Summers, PT, DPT, Heidi Prather, DO, Aaron Chamberlain, MD
22

The Medical Program
for Performing Artists
rehabilitated Alicia Graf Mack,
dancer with the Alvin Ailey
American Dance Theater, now
on a 24-city tour.

HIS YEAR, DEVYANI HUNT, MD, HAD AN EPIPHANY.
During Dancing in the Streets, a St. Louis outdoor
festival featuring more than 60 dance companies and
1,000 dancers, Hunt saw many dancers who might not

Encore!
have been on stage without her help. In one instance, Hunt
realized she had treated 10 of a company’s 18 dancers.

“It was great to see that,” said Hunt, a physiatrist

When the
healing arts
enhance
the arts
BY DEB ARONSON

and associate professor in the Department of Orthopedic
Surgery. “It was an ‘aha’ moment for me that I really am
making a difference.”
Along with physical therapist Lynnette Khoo-Summers,
FACING PAGE: BERNIE ELKING • UPPER RIGHT: ANDREW ECCLES • LOWER RIGHT: RAY MARKLIN

PT, DPT, Hunt co-directs Washington University’s Medical

Professional performance
demands a finely tuned
instrument: The human body.

Program for Performing Artists (MPPA). This program helps
a variety of arts professionals — musicians, dancers, circus
acrobats, ice skaters, painters and singers — return to
their beloved stage, abiding passion and, in many cases,
their livelihood. Frequently, without the help of the MPPA
team, these unique patients might have to give up the very
things that animate their lives.

outlook.wustl.edu
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Poetry in motion:
Devyani Hunt, MD (left),
and Lynnette KhooSummers, PT, DPT, evaluate
Marcus Johnson, a Webster
University dance major
and instructor at
Denoyer Dance in
St. Louis.

P PA C L I N I C I A N S primarily treat
local artists but also see performers
from many different tours — “So You
Think You Can Dance,” Disney on Ice
and Cirque du Soleil, for example — performing
locally at The Fabulous Fox Theatre, the Blanche M.
Touhill Performing Arts Center or other venues.
Last year, during the St. Louis production of
“The Lion King,” one of the lead actors, outfitted with a heavy headpiece, suffered acute neck
pain. The role was physically demanding, Hunt
explains, and the actor no longer could perform in
costume. In the clinic, Hunt diagnosed him with a
pinched nerve and treated him to decrease inflammation and muscle spasms. Khoo-Summers also
addressed the muscle spasms, and taped his shoulder girdle to provide more support. Within a few
days, he rejoined the “Lion King” cast.
Hunt once treated a physical comedian from
Branson, Mo., who injured himself after doing the
splits nightly for 15 years. “He wasn’t one to be
told not to do the splits anymore!” Hunt said.
Performing artists use their bodies
more intensively and repetitively than
most people. Musicians might do the
same movement with their bow arm
hundreds of thousands of times in
learning a piece of music. Dancers
and circus performers repeat
precision movements day
after day. Strain injuries
are common.
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Functioning within “normal” limits simply is
not good enough. St. Louis Symphony cellist Alvin
McCall found he could not exert enough force on
the end of his bow. Because of damage to his ulnar
nerve, his fingers were sluggish. Initially, McCall’s
doctor told him that the strength in his left hand
was “within the normal range.”
“Diagnosticians and therapists have to understand the demands you make on your body,” said
McCall’s wife, Anna Lackschewitz, who is also
a professional musician. “Lots of doctors just
shrugged off his concerns about needing a higher
level of performance.” Another doctor told him
‘wait and see.’ They have no appreciation that this
is our livelihood.”
Not so with the MPPA, where McCall found
support and help to strengthen weak muscles and
adapt his playing style. Lackschewitz and McCall
were so happy with how McCall was treated that
they referred all four of their children, two who
now dance professionally. Recently, Lackschewitz,
principal violist of the Fox Theatre Orchestra,
underwent therapy for a pinched nerve in her neck.
The MPPA was established in 1988 by the late Jerome
Gilden, an orthopedic specialist in the School of
Medicine and Barnes-Jewish Hospital. He retired
in 1998, but, in 2004, the program was revived
by Hunt, Khoo-Summers and Heidi Prather, DO,
orthopedic surgery professor and chief of the
section of physical medicine and rehabilitation.
Prather and Hunt are physiatrists — specialists in
physical medicine and rehabilitation who focus
on non-surgical musculoskeletal care. They excel
at linking symptoms to root causes and, unlike
orthopedic surgeons, are not body-part specific.
Two years ago, Aaron Chamberlain, MD, a
shoulder and elbow surgeon and assistant professor of orthopedic surgery, joined the group.
Because of their experience as performing artists,
they bring zeal and understanding to their clinical
work: Hunt and Khoo-Summers as dancers,
Prather on trumpet and Chamberlain on violin.
“We understand where they (the artists) are
coming from,” said Khoo-Summers, who danced
professionally in Chicago before injuring her
knees. Now an assistant professor in the Program
in Physical Therapy and the Department of
Orthopedic Surgery, she found her niche in rehabilitating performing artists. “We understand that
need to perform, to make your body do things it
is not built for. Most often, if you go to clinicians
who don’t understand that need to perform,
they’ll say, ‘If it hurts to dance, don’t dance.’”
Winter 2013–14
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Encore!

Together, Hunt and Khoo-Summers diagnose
problems by observing patients in motion. In
addition to traditional exercise equipment, such
as treadmills, an elliptical, bikes and a universal
gym, the physical therapy clinic boasts a ballet
barre and special flooring for dancers.
“If you test performing artists in the office in
standard fashion to see if they have good muscle
strength, their strength will be fine,” she said.
“But if they can’t maintain the posture they need
because of fatigue, then you have to develop a
training program to work more toward endurance
and posture retraining.”
While the MPPA physicians’ efforts help
decrease symptoms, Khoo-Summers corrects
the movement impairments that are causing the
symptoms. This is done by attaining better alignment, correcting muscle imbalances, building
stamina and developing adaptive strategies.
“The MPPA is cutting edge —
designed to maintain high levels
of performance in those who push
the limit of what is physically possible on a sustained basis,” said
Richard Gelberman, MD, the Fred
C. Reynolds Professor and chair
of the Department of Orthopedic
Surgery. “The clinicians are to be
congratulated for bringing exceptional care for this ultra-committed population to St. Louis and
LYNNETTE KHOO-SUMMERS, PT, DPT
to our region.”

“We understand
that need to
perform, to
make your body
do things it is
not built for.”

Not surprisingly, the field of performing arts
medicine is a small and tight-knit community.
There are fewer than 50 such programs nationwide
and many have sprung up in cities with major performing arts centers. Harkness Center for Dance
Injuries, for example, was founded in 1989 in
response to the New York dance community’s critical need for specialized and affordable health care.
Washington University’s program, while not one
of the nation’s largest, is well known and respected.
“Washington University’s program in performing arts is a wonderfully integrated and multidisciplinary program,” said Monica Rho, MD,
assistant professor of physical medicine and rehabilitation at Northwestern University’s Feinberg
School of Medicine. “Dr. Hunt worked hard to
develop a clinic where both she and Lynnette
co-evaluate and co-treat the patient. The coordination of these services places the performing artist’s
needs first and makes Washington University’s
program a model to emulate.”
outlook.wustl.edu

Such coordination may
sound simple, but most programs cannot coordinate co-evaluations, said Rho,
who also sees performing artists in her practice.
Because it’s critical for these artists to maintain
their performance schedules, the MPPA team
offers same-day appointments whenever possible.
Besides working in the clinic, Hunt or KhooSummers often are on-call or backstage at performances. Recently, Khoo-Summers accompanied
Dance St. Louis pro bono on a three-city tour.
Because most patients have chronic overuse
injuries, it’s important that artists adopt preventive
strategies early in their careers. The MPPA holds
outreach programs with young dancers, musicians
and circus performers, recently leading a symposium for Wester University’s Department of
Music and Community Music School.
But no matter how much prevention they
preach, injuries will occur. With proper intervention, however, injuries don’t have to result in a
sidelined career; performing artists can get back
on the road and back to following their passion.

Warming up for a
Metropolitan Orchestra
of St. Louis concert: Alvin
McCall, St. Louis Symphony
cellist, and his wife, Anna
Lackschewitz, principal
violist of Fox Theatre
Orchestra, who both
were treated through
the Medical Program for
Performing Artists.
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Leading Together

The Campaign for Washington University

Infectious
diseases and
global health
Improving health is among the world’s most pressing challenges,
and infectious diseases research has become one of the largest areas
of concentration within the School of Medicine. As new diseases
appear, there is an ever-greater risk of rapid transmission and spread
The global reach of
Washington University
extends to sub-Saharan
Africa. Mark Manary, MD,
the Helene B. Roberson
Professor of Pediatrics,
developed a revolutionary
peanut butter-based
therapeutic food to
combat severe childhood
malnutrition. A proven
lifesaver with a 95 percent
recovery rate, the blend has
become standard treatment
worldwide.

of infection. By traveling to foreign countries to provide basic
health care or by offering programs in St. Louis aimed at preventing
sexually transmitted diseases, our faculty, students and staff are
dedicated to making a difference — locally, nationally and globally.
Research in the gut microbiome, hospital-acquired infections,
and parasitic diseases are but a few examples of the breadth and
depth of our leadership. The potential to solve some of the most
vexing questions of population health is growing as our research
teams forge a rapid pace toward discoveries.
Private philanthropy is essential to advance the initiatives
described in the following pages.

GARETH BENTLEY

Partner with us in support of these initiatives.
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Vicky Fraser with
residents in hospital

Victoria J. Fraser, MD, and her team lead infection control training programs in health care and community settings.

No place for infection
Hospital-acquired infections (HAIs) remain
a significant cause of illness and death. Too frequently, bacteria or other microorganisms lurking on medical devices, bed rails, a bandage or a
caregiver’s hands find their way into a patient’s
body via a wound, catheter, ventilator or invasive
procedure.
School of Medicine researchers have developed
infection surveillance and control
guidelines that have been adopted
worldwide.
Despite these measures, new
virulent, antibiotic-resistant pathogens such as methicillin-resistant
Staphylococcus aureus (MRSA) and
Washington University
Clostridium difficile have emerged.
People are living longer, but also are
researchers have developed
more susceptible to HAIs —through
infection surveillance and
advances in cancer therapy, the
control guidelines that have
use of immunosuppressants and
been adopted worldwide. long-term management of multiple
chronic diseases. “The key to preventing the spread of infections is
vigilance and attention to strict patient care guidelines,” said Victoria J. Fraser, MD, the Adolphus
Busch Professor and chair of the Department of
Internal Medicine and a world-renowned infectious
diseases expert.
28 Washington University School of Medicine

Among critical advances made by the medical
school’s infectious disease research team and BJC
HealthCare Infection Prevention Consortium:

• Safer IV insertion techniques and use of

the antibacterial antiseptic chlorhexidine to
lower the risk of bloodstream infections. In
10 years, central line-associated bloodstream
infections in the U.S. decreased 60 percent.

• Standardized procedures to reduce surgi-

cal site infections, including improved hand
hygiene, skin antiseptic use, clippers instead
of shaving, perioperative glucose control,
better temperature control in the operating
room and precise timing of antibiotic use.

• Improved patient management policies —

including elevating the head of hospital
beds, use of disinfectant mouthwashes and
standardized order sets to wean patients off
ventilators and sedatives — which reduced
ventilator-associated pneumonia in ICUs.
This campaign, named “Whap VAP,” subsequently was replicated across the country.

Our ability to advance research, recruit the
best individuals and train health care workers
to protect patients is greatly helped by private
philanthropy.
Winter 2013–14

With support from FIHTM, students designed and implemented a diabetes prevention program in Majuro, Republic of the Marshall Islands.

Life-changing journey
Interest in global health among U.S. medical

students has grown dramatically. But, only a small
fraction of students who work overseas during
medical school will pursue careers in international health.
Faculty say it is clear, however, that early international experiences can have long-term impact on
medical students and their future patients. Global
training broadens students’ perspectives on disease prevention, care
delivery and health care systems.
The Forum for International
Health and Tropical Medicine
(FIHTM) is a student-led group
“Through FIHTM, the
devoted to promoting interest and
medical school is
understanding of global health at
preparing young
the School of Medicine. With support
from the dean’s office and the
doctors who will work
Washington
University Medical
to change the world.”
Center Alumni Association, FIHTM
— GARY WEIL, MD
annually sponsors one- to twomonth overseas electives for 25 students and spring break experiences
in the Navajo Nation and Central America.
FIHTM fellows participate in a wide range of
research and clinical activities, such as studying
tuberculosis in India, working on malaria prevention in rural Uganda and examining respiratory
outlook.wustl.edu

disease in stonemasons in Colombia.
“Many of our students say their international
experience was life-changing,” said Gary Weil,
MD, professor of medicine and faculty adviser to
FIHTM. “They quickly learn to adjust to reduced
resources and they see that culture, behavior and
environment dramatically affect health, outcomes
and the delivery of care.”
Working with diverse populations in lowresource settings requires students to rely heavily
on physical exams and the patient’s history to
make a diagnosis. These electives often strengthen
“soft” skills, such as compassion and cultural
sensitivity, which are valuable regardless of where
students practice.
“It taught me how to establish a rapport with
patients in spite of a language barrier and to see
things from another cultural perspective,” said
Christelle Samen, a second-year medical student
who completed a rotation in Guatemala.
Student demand for these experiences outpaces
the resources of FIHTM. Private philanthropy can
support summer internships around the globe.
“There’s a growing interest in global health
issues, and many of these issues are relevant to
U.S. medical practice and policy,” Weil said.
“Through FIHTM, the medical school is preparing
young doctors who will work to change the world.”
Outlook 29

Global Health Scholars learn sensitivity to other cultures and develop solutions in resource-limited environments, such as this ICU in Guatemala City.

Worldview of health
A catalyst for innovation, the Global Health

Scholars in Medicine program takes residents
out of the academic medical setting with its latest
technologies and collaborative, multidisciplinary
teams and places them in underresourced parts
of the world.
On these month-long rotations, medical residents hone their skills — overcoming language
barriers, broken equipment and cultural sensitivities. Often, they work
without the benefit of a translator,
attending physician or nearby lab.
These new physicians gain a
global mindset, understanding not
These new physicians
only disease, but also the impact of
gain a global mindset, culture and poverty on public health.
Ten residents are selected yearly
understanding not only
to
participate
in the highly competidisease, but also the
tive program administered by the
impact of culture and
Department of Internal Medicine.
poverty on public health.
The program began in 2007 with
support from Jack Ladenson, PhD,
the Oree M. Carroll and Lillian B.
Ladenson Professor of Clinical Chemistry.
Ladenson and David Windus, MD, professor of
medicine, led residents to Eritrea and Bhutan to
create diabetes education and disease management programs.
30 Washington University School of Medicine

Now it includes more faculty and sites in
Honduras, India, Japan and Guatemala. Also,
the program offers a locally based “international”
rotation: students work with refugees and the
homeless in St. Louis — people they might not
typically see during an inpatient rotation — at
Family Care Health Centers and Casa de Salud.
Scholars conduct research, develop outreach
initiatives and share best practices.
“It strengthens several aspects of our curriculum, including training in cultural sensitivity and
preventive care,” said Melvin Blanchard, MD,
FACP, chief of the Division of Medical Education.
“As a university with a global view, we hope that
our trainees develop an appreciation for the wider
world in which we live and become engaged in a
manner that advances longevity and a high quality
of life in our immediate community and abroad.”
Rachel Kilpatrick, MD, an endocrinology fellow
at the School of Medicine, finished a rotation in
Eritrea and now hopes to work with Hispanic
immigrants. “I’m motivated to work with the
underserved here in the United States, particularly
with immigrant populations that may have difficult access to care,” she said. “My time as a Global
Health Scholar was one of the most valuable
experiences of my entire medical training so far.”
Winter 2013–14
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A study of young twins living in Malawi showed that intestinal bacteria play a key role in malnutrition. Center: Jeffrey Gordon, MD, is senior author.

Ending malnutrition
International leaders in addressing childhood

malnutrition, Washington University researchers
are working to devise innovative solutions.
Jeffrey Gordon, MD, the Dr. Robert J. Glaser
Distinguished University Professor and director
of the Center for Genome Sciences and Systems
Biology, leads an international team of scientists trying to understand how gut microbes (the
“microbiota”) help determine nutritional status.
Recent study findings point to
a role for the microbiota in childhood malnutrition. The research,
published in the journal Science,
involves 317 sets of twins in Malawi
followed from birth to age 3.
Childhood malnutrition is all
Researchers believe there
too
common, and scientists wonis a link between gut
der why some children are afflicted
microbes and the diets of
but not others, even those in the
malnourished children. same household who eat the same
foods. Gordon and his team focused
on twin pairs in which one child
remained healthy and the other became malnourished. This ‘discordance’ occurred equally in
fraternal and identical twins, suggesting an underlying factor besides human genetics. So the team
turned to the microbiota.
outlook.wustl.edu

Therapeutic food interventions reduced
mortality in children with severe undernutrition,
but healthy growth was not completely restored
and proper neurodevelopment lagged.
The team found that the microbiota of
malnourished children appeared immature.
Therapeutic foods helped, but once they were
stopped, the immature state reappeared.
By transplanting microbiota from twins into
formerly sterile mice, the researchers showed that
the combination of immature microbiota from a
malnourished child and a Malawian diet produced
disease in recipient animals; this was not the case
when mice received a healthy child’s microbiota.
Their work provides a microbial view of human
postnatal development and suggests that healthy
growth requires a properly maturing microbiota.
An important implication is that prolonged
food-based interventions and/or addition of gut
microbes may be needed for durable repair of
microbiota immaturity in childhood malnutrition
and improved clinical outcomes.
“With support of the Bill & Melinda Gates
Foundation, we are studying the gut microbiota in
malnourished children living in other low-income
countries, and working to develop new types of
safe, effective interventions to treat and ultimately
prevent this devastating disease,” Gordon said.
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COURTESY OF DAVED FREMONT, PHD

Researchers are investigating how humans respond to potentially lethal viruses such as West Nile, modeled above.

Targeting viral dangers
Washington University has broad research
focused on the viral causes of infectious disease.
Stephen Beverley, PhD, is researching viruses
that make parasitic diseases more dangerous.
In doing so, Beverley, the Marvin A. Brennecke
Professor and chairman of the molecular microbiology department, is forging a pathway in his
field, which he calls “parasite virology.”
In 2011, Beverley’s team, working
with scientists at the University of
Lausanne in Switzerland, found
that a particular virus increased
the severity of a parasitic disease
called Leishmaniasis.
About 12 million people are
infected worldwide with this potentially lethal disease, and 2 million
new cases develop each year.
Emerging viruses
“The fact that there was a viral
pose constant threats
target within the Leishmania parato public health. site immediately led us to thinking
that an antiviral therapy could
control the spread and impact of
the disease,” Beverley said. “We’re now exploring
several leads in this area.”
Michael Diamond, MD, PhD, professor of
medicine and an expert on West Nile virus, is
part of a new multi-institution collaboration
32 Washington University School of Medicine

looking for similarities in how humans respond
to three potentially lethal viruses.
The National Institutes of Health (NIH)
study will focus on West Nile, Ebola and influenza, using advanced computational models
to find common traits. Diamond expects that
finding similarities could lead to new, more
effective treatments.
David Wang, PhD, associate professor of
molecular microbiology and pathology and
immunology, was part of an important team in
2003 that successfully hunted down the severe
acute respiratory syndrome (SARS) virus.
Emerging viruses pose constant threats to
public health. Today, Wang continues efforts
to identify and characterize novel viruses.
His current research attempts to understand
why 70 percent of viral encephalitis cases and
30 percent of respiratory tract infections defy
the most sophisticated diagnostic tests now used
— suggesting that unknown agents likely are
involved in the pathogenesis of these diseases.
Philanthropy plays a vital role in funding
fellowships and research opportunities. Support
from donors is critical to our continued leadership in infectious diseases.
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classnotes
1940 S

1950 S
Bernice Oshita, NU 50, was honored by
The American Red Cross as a “Volunteer of
the Week” for contributing 10,716 service
hours to the Tripler Army Medical Center
in Honolulu. She describes herself as the
“gofer,” lending a hand as needed in the
office and helping nurses.
Rudenz “Rudy” Douthat, MD 54, was
honored at the American College of
Emergency Physicians (ACEP) Scientific
Assembly as one of two surviving founders of emergency medicine and ACEP.

1960 S
Ronald Evens, MD 64, has been appointed
chairman of the Board of Regents for the
National Library of Medicine (NLM), the
world’s largest medical library. The NLM
board guides the library as it manages the
worldwide flow of medical information.
Josh Grossman, MD 65, colonel (retired),
U.S. Army Medical Corps, MD, FACP, spoke
to the Washington County Bar Association
on “Landmark Medical Ethical Matters.”
Michael Treister, MD 67, attended the
National Flute Association annual convention. As a previous chair and current
member of the Performance Health Care
Committee and Editorial Board, Treister
enjoyed getting away from the office to
“jam” with other flautists.

1970 S
Francisco Garriga, MD 70, published
Tell Me How You Die Easy, a book aimed at
educating medical and nursing students
on the importance of compassionate care.
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Carl Woolsey, MD 43, is retired and living in
Salt Lake City. He enjoys “being with his
family, drinking whiskey and telling lies
with friends, relatives and neighbors.” He is
proud to have three generations of OB/GYNs
in the same family practice and hospital.

Distinguished Alumni Scholars honored

Four first-year
medical students recently were honored as Distinguished Alumni Scholars. Each
scholarship is named to honor an alumnus or alumna who has served on the School
of Medicine faculty. Distinguished alumni honorees and scholars, from left: Jeffrey
Marinshaw; William F. Stenson, MD 71; Kevin Li; Leonard Bacharier, MD 92; Jordan
Jacquay; Linda Peterson, MD 90; and Michael Madigan.

Scott Frankel, MD 79, an allergy specialist with Kansas City Allergy & Asthma in
Overland Park, Kan., was named a
“Top Doctor” by U.S. News & World
Report and Castle Connolly Medical Ltd.
Cecil Holliman, MD 79, presented the
opening plenary lectures on “Trauma
System Development” and “Prehospital
Trauma Triage” at the 2013 International
Conference and Training on Emergency
Trauma Care held in Vietnam last March.
Holliman is president-elect of the
International Federation for Emergency
Medicine.

1980 S
David Baltzer, HA 81, has been elected
to the Board of Directors of the Missouri
Health Executives Group, the state chapter
of the American College of Healthcare
Executives, and will chair the communications committee.
Ayse Kilfoy, DE 87, was named to St. Louis
Magazine’s “Top Dentists” list for the fifth
consecutive year.

1990 S
Kirk Gasper, MD 93, was promoted to
U.S. Navy captain and served as a senior
medical officer at the Naval Branch Health
Clinic in Bahrain. In August, he returned

to Oak Harbor, Wash., to his family, which
includes Michele (Francoeur) Gasper,
MD 93, who also serves in the Navy.
Tadd Pullin, HA 94, GR 94, was named
senior vice president of marketing and
strategy development at the Nebraska
Medical Center in Omaha, where he provides senior oversight for marketing, strategic planning and human resources.
Brett Kissela, MD 95, has been appointed
the Albert Barnes Voorheis Chair of
Neurology and Rehabilitation Medicine at
the University of Cincinnati (UC) College
of Medicine and UC Health, effective Jan.
1, 2014. He joined the neurology department as an assistant professor in 2000.

2000 S
Marc Herant, MD 00, will spend the next
two years in Rwanda as an adviser to the
Ministry of Health.
Elizabeth Foglia, MD 05, is completing
a neonatology fellowship at Children’s
Hospital of Philadelphia this fall and will
transition to a faculty clinical research
position and study neonatal resuscitation. Her husband, Ted Satterthwaite,
MD 06, works in imaging research in the
Department of Psychiatry at the University
of Pennsylvania. They recently welcomed
their third child.
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Leana Wen, MD 07, co-authored the book
When Doctors Don’t Listen: How to Avoid
Misdiagnoses and Unnecessary Tests.
She is an attending physician and director
of patient-centered care research in the
Department of Emergency Medicine at
George Washington University.

In Memory
Ernesta Grace Mira, NU 41
Mira died Thursday, Aug. 1, 2013, at age
95. Mira grew up in Roodhouse, Ill., and
dreamed of becoming a nurse. Upon
graduating from Washington University,
she was called to active duty in the Army
Nurse Corps and sent to O’Reilly General
Hospital in Springfield, Mo. Later, she
opened a medical practice in Alton, Ill.,
with her husband Joseph Mira, MD 41,
who preceded her in death.
Charles Nicolai, LA 43, MD 46, HS
Nicolai died Friday, May 31, 2013, at the
age of 91. He completed undergraduate and medical degrees at Washington
University before serving in the U.S. Navy
Medical Corps from 1947-49. After the
war, he returned to the university and cofounded the Division of Urology in 1953.
For a time, Nicolai practiced urology at
Missouri Baptist and Deaconess hospitals,
serving as chief of staff and chief of urology. Nicolai returned to the School of
Medicine in 1990 in the office practice
of Urology and Prostatic Cancer research
until retiring in 2005. He was a founding and life member of the Society for
Pediatric Urology, a fellow of the American
Academy for Pediatrics and a consultant
to the Shriners Hospitals for Children. He
was a 32 degree Master Mason K:C:C:H.
Moolah Shriner.
Margaret Burge McChesney, MD 49
McChesney died Friday, April 26, 2013, in
Newport News, Va. She is remembered as
a devoted wife, mother and pediatrician.
David Reed Holmes, MD 51
Holmes died Sunday, March 17, 2013,
at age 90. A graduate of Missouri State
Teachers College in Springfield, Mo.,
Holmes joined the U.S. Navy during World
War II and became a pilot. He attended
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the School of Medicine and opened a
general practice in Warrensburg, Mo. He
later returned to Washington University
to become an OB-GYN, completing an
infertility fellowship. For 30 years, Holmes
practiced as an OB-GYN in Springfield,
delivering 9,000 babies. At one point,
he was the only infertility specialist in
Southwest Missouri.
Henry Baker Lorentz, DE 53
Lorentz died Tuesday, Feb. 12, 2013, at
Peace Hospice in Great Falls, Mont. He was
86. Lorentz earned a bachelor’s degree
from Montana State College and attended
Washington University Dental School.
During World War II, he served as a naval
air gunner and later joined the Army
Dental Corps. A practicing dentist for 40

years, Lorentz was elected president of
the Montana State Dental Association and
was honored for distinguished service by
the Montana State Dental Society.
Mitchell E. Goldenberg, LA 52, MD 55
Goldenberg, a plastic and reconstructive
surgeon in Northwest Indiana for more
than 40 years, died Sunday, Jan. 20, 2013,
at age 81. After attending Washington
University for undergraduate and medical
studies, he completed a general surgery
residency at Albert Einstein Medical
Center in Philadelphia, a plastic surgery
residency at Meadowbrook Hospital in
Hempstead, N.Y., and a hand surgery fellowship at Memorial Sloan Kettering. He
served as a U.S. Army captain and as a
physician in a MASH unit in Korea.
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classnotes
Gregory Clawson Rosenberger, PT 59
Rosenberger, a physical therapist for 34
years in Indiana, Iowa and Wisconsin,
died Monday, June 17, 2013, at age 82.
He served in the U.S. Army for three years
during the Korean Conflict. Rosenberger
earned a bachelor’s degree in physical
therapy from Washington University and
a master’s degree in public health from
the University of Michigan. He particularly
enjoyed working with elderly patients.
O. Michael Colvin, MD 61
Colvin, a prominent cancer researcher,
died Saturday, March 16, 2013. He was
77. Born in Princeton, Ind., he graduated from Indiana University in 1957 and
Washington University School of Medicine
in 1961. He completed an internal medicine internship and residency at Johns
Hopkins University. Following a fellowship
at the National Cancer Institute, Colvin
worked at Johns Hopkins for 30 years
— as a professor of medicine and pharmacology, director of the pharmacology
division, research director for the oncology
center and associate dean for research.
Colvin later moved to Duke University,
becoming director of its cancer center
and the William W. Shingleton Professor of
Cancer Research and professor of pharmacology and cancer biology.
Perry Dyson Inhofe II, MD 88, HS 89
Inhofe died unexpectedly Sunday, Nov. 10,
2013, of injuries sustained from a plane
crash. He was 52. Inhofe completed an
undergraduate degree, first in his class,
in biomedical and electrical engineering
from Duke University in 1984. He earned a
medical degree at Washington University
and completed an internship at Barnes
Hospital and residency at the University
of Oklahoma College of Medicine,
Orthopedic Surgery and Rehabilitation.
Inhofe met his wife, Nancy Rader Inhofe,
MD, at Washington University when he
rotated through the Pediatric Emergency
Department. They were married in 1989.
Inhofe was an active orthopedic surgeon
at Central States Orthopedics in Tulsa,
Okla. He was the son of U.S. Sen. James
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Inhofe with whom he shared a love of flying. He is remembered as a devoted and
loving husband, father, son and physician.
Andrew Zupan, LA 84, MD 92, GM 92
Zupan, a pediatrician in St. Peters, Mo.,
died Friday, Feb. 15, 2013. He was 50.
Originally from Columbus, Ohio, Zupan
completed undergraduate studies at
Washington University and earned an
MD/PhD from the School of Medicine.
Zupan completed a pediatrics residency at
Cincinnati Children’s Hospital. He practiced
pediatrics in Batesville, Ind., and later in
Washington and St. Peters, Mo.

Faculty
Bernard Becker, GR 90
Becker died Wednesday, Aug. 28, 2013,
at his Central West End home. He was
93. Becker grew up in Brooklyn, N.Y., and
graduated from Princeton University and
Harvard Medical School. He trained as a
U.S. Army psychiatrist during World War
II and later in ophthalmology at Johns
Hopkins University. Becker is largely
known for his work to find glaucoma
treatments. During the 1950s, he helped
Washington University medical school
build its Department of Ophthalmology
and Visual Sciences, and headed it for 35
years. Additionally, he helped establish the
National Eye Institute. Becker donated a
600-volume collection of medical books
to the medical school and, in 1995, the
medical library was renamed in his honor.
Thomas B. Ferguson, HS 57
Ferguson, professor emeritus of cardiothoracic surgery, died Sunday, May
26, 2013, at age 90. A pioneer in heart
surgery, Ferguson helped bring the first
heart-lung machine to St. Louis in the
late 1950s. In 1958, he and his colleagues
performed Washington University’s first
open-heart surgery with the aid of the
new heart-lung pump. A graduate of the
Duke University medical school, Ferguson
trained in surgery at Duke, Barnes Hospital
and Washington University. Except for four
years in private practice, Ferguson spent
his career at Washington University, training residents and fellows in cardiothoracic
surgery and serving on the admissions

committee. He was president of the
American Association for Thoracic Surgery
and the Society of Thoracic Surgeons, of
which he was a founding member.
Elmer Brown Jr., MD 50
Brown, a distinguished hematologist
and emeritus professor of medicine, died
Saturday, Sept. 8, 2012, at his home in
Dana, N.C. He was 86. A native of New
York City, he attended Oberlin College,
then earned a medical degree from
Washington University. After a residency
at Columbia-Presbyterian Center in New
York, Brown served two years in the U.S.
Naval Medical Corps. Afterward, he trained
in the Division of Hematology at Barnes
Hospital, serving for nine years as division
chief before becoming associate dean for
postgraduate education.
Charles Ward Parker, MD 53
Parker died Tuesday, April 23, 2013, at his
home in Webster Groves, Mo. He was 83.
His pioneering research helped improve
treatment of allergies and asthma. Parker,
who founded the university’s Division
of Allergy and Immunology in the early
1960s, served on the faculty for more than
four decades. Parker attended Washington
University for undergraduate and medical
studies. Afterward, he spent two years in
the U.S. Navy before completing an internal medicine residency at Barnes Hospital
and serving as chief resident. Parker took
emeritus status in 1998, but continued to
work in his lab.
Thomas H. Steinberg, MD
Steinberg, associate professor of medicine,
died Sunday, June 16, 2013, in St. Louis of
complications from amyotrophic lateral
sclerosis. He was 61. A cell biology
researcher and infectious diseases physician,
Steinberg joined the School of Medicine’s
Division of Infectious Diseases in 1989.

If you wish to make a tribute gift in honor
of any of the above alumni or faculty, please
contact: Pamela Buell, Washington University
Medical Alumni and Development, Campus Box
1247, 7425 Forsyth Blvd., Suite 2100, St. Louis MO
63105-2161, (314) 935-9691.
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EXHIBIT

COURTESY OF THE ARTIST

Not many art careers begin in a pathology lab. As a teenager, Marilynne Bradley illustrated a
lab’s blood chemistry book, helping her earn a chemistry scholarship to Washington University.
She studied pre-med, but eventually committed fully to art. The Webster Groves (Mo.) Arts
Commission recently presented Bradley, FA ’60 — a watercolorist, illustrator, historian and
educator — with its Lifetime Achievement in the Arts Award and St. Louis Mayor Francis Slay
declared Oct. 11, 2013, “Marilynne Bradley Day.” Her works are showcased around the world
in museum exhibits and corporate collections. Following cataract surgery at the Center
for Advanced Medicine, Bradley saw the Medical Center through fresh eyes. The resulting
paintings are on exhibit in the Farrell Learning and Teaching Center through February 2014.
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